Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2024 Scrip Asia 100

Explore APAC industry trends brought to you by experts in clinical trials, manufacturing, and more.

VIEW NOW

Featured Stories


J&J’s Growth Plan Calls For Mega-Blockbusters And A Leading Oncology Franchise

Johnson & Johnson laid out long-term revenue growth guidance and plans for its Innovative Medicines pipeline during an R&D day.

Research & Development Leadership Launches

Time For Oral Incretins To Prove Their Worth

Several crucial trial readouts in diabetes and obesity will come this year and next, and the stakes are high.

Clinical Trials Metabolic Disorders Companies

Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer

Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.

Clinical Trials Drug Approval Standards Business Strategies

Asia Spotlight

Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling

In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.



India Commercial

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Stock Watch: Immunity Debt And Vaccine Investment

A rise in childhood pneumonia in China and The Netherlands raised fears of another pandemic but the variety of identified pathogens gave way to the concept of ‘immunity debt’ resulting from the last pandemic.

Pipeline Watch: Eight Approvals And 15 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms

Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.

Executives On The Move: Sypre Therapeutics, Evelo Biosciences, Amylyx Pharmaceuticals And More

Recent executive moves in the industry include changes at the top at Spyre Therapeutics, Neopharmed Gentili and CytoDyn.

Interviews

AstraZeneca Likes What Chinese Innovation Has To Offer

Chinese drugmakers’ “ability to move quicker at pace and with purpose” than counterparts in the US, Europe and other parts of the world underlies increasing deal activity with big pharmas, AstraZeneca’s BD chief Shaun Grady tells Scrip

Astellas Exec On Tech Tools For Better Go-No-Go Decisions, Gen AI

Astellas’s senior director, head of enterprise insights and digital solutions, digital, analytics and technology tells Scrip how data analytics and deductive hypothesis-oriented simulation are driving improved strategic decision-making across the organization. He also outlined some early generative AI use cases and the promise of digital twins in medicine.

Ambitious Almirall Lays Out Ebglyss Launch Plans

The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

See All
Graphics

Corporate VCs Play A Bigger Role In Hard Times

The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.

Biotech IPOs Get Bigger, But Not Necessarily Better

The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.

ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.

See All
Recent Stories

Novartis’s Fabhalta Reaches First Stop On Regulatory Journey With PNH Nod

Novartis envisions the drug, the first oral monotherapy for PNH, as a “pipeline in a pill” that could see $3bn in peak sales, with a Phase III readout in IgAN in October and one in C3G expected this month.

Radiopharmaceutical Leader ITM Gets A Burst Of Energy – And Weighs Up Going Public

ITM is reaping benefits from long-term investment in radiopharmaceuticals manufacturing and is now looking to challenge its customer, Novartis, by bringing its first product to market.

Efficacy, Not Safety, Does For Merck KGaA’s BTK Inhibitor

Evobrutinib flunked its Phase III multiple sclerosis program not because of its known toxicity, but because it didn’t work.

AstraZeneca Likes What Chinese Innovation Has To Offer

Chinese drugmakers’ “ability to move quicker at pace and with purpose” than counterparts in the US, Europe and other parts of the world underlies increasing deal activity with big pharmas, AstraZeneca’s BD chief Shaun Grady tells Scrip

Astellas Exec On Tech Tools For Better Go-No-Go Decisions, Gen AI

Astellas’s senior director, head of enterprise insights and digital solutions, digital, analytics and technology tells Scrip how data analytics and deductive hypothesis-oriented simulation are driving improved strategic decision-making across the organization. He also outlined some early generative AI use cases and the promise of digital twins in medicine.

Stock Watch: Immunity Debt And Vaccine Investment

A rise in childhood pneumonia in China and The Netherlands raised fears of another pandemic but the variety of identified pathogens gave way to the concept of ‘immunity debt’ resulting from the last pandemic.

Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment

The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.

Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?

Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.

CRISPR Overhauls CAR-T Pipeline With Next-Gen Candidates, Autoimmune Expansion

Experts see allogeneic CAR-Ts as less likely to carry potential risks of T-cell malignancies, and an opportunity for differentiation against the crowded autologous CD19-directed CAR-T space.

Ambitious Almirall Lays Out Ebglyss Launch Plans

The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.

China Seniors' Rising HIV Rates Pose Control Challenges

Although the spread of HIV/AIDS appears to be largely under control in China, increasing infections among the elderly are causing concern due to a range of risk factors, while domestic firms move to expand their drug offerings.

UsernamePublicRestriction

Register